The First Klebsiella pneumoniae Isolate Co-Producing OXA-48 and NDM-1 in Turkey

Resistance to broad-spectrum antimicrobials is a well-known challenge in treating Enterobacteriaceae infection worldwide.Carbapenems are an important class of antimicrobials used in treatment against these organisms, although increasing resistance to carbapenems has been reported among Enterobacteriaceae [1].The production of OXA-48 was first described in Klebsiella pneumoniae isolates from Istanbul [2].Although most reports describe single cases [3], important outbreaks have also been reported.K. pneumoniae and other Enterobacteriaceae strains with OXA-48 carbapenemase are now spreading from the Middle East to Europe, Asia, and North America.In addition, NDM-1 (another carbapenemase) was first identified in a K. pneumoniae isolate from a Swedish patient who had been treated in India in 2009 [4].NDM-1 has since been reported in numerous isolates, predominantly in Escherichia coli and K. pneumonia, in many countries, including the United Kingdom, India, Pakistan, and Bangladesh [1].Between June 2010 and May 2013, we collected 887 Enterobacteriaceae isolates from patients who were admitted to the Gulhane Military Medical Academy.All isolates were tested for susceptibility to 19 antimicrobials by using the Phoenix System